Plymouth Township-based DeNovo Sciences Inc., a developer of systems for single cell analysis, today announced it has received a U.S. patent for its microfluidic system for rare cell capture and analysis. It’s the company’s first patent.
"The issuance of this patent marks a great validation of our technology," says Priya Gogoi, co-founder and vice president of research and strategy at DeNovo. "So many companies are competing in the field of liquid biopsy that it has become extremely important for us to distinguish ourselves from other technology providers."
Liquid biopsies are non-invasive blood tests that detect circulating tumor cells and fragments of tumor DNA that are shed into the blood from the primary tumor.
Gogoi says DeNovo's technology revolves around a transparent, microfluidic chip that captures and segregates circulating tumor cells as single cells or clusters, which allows for single cell analysis or retrieval. The system allows blood samples to be processed without any pre-processing like centrifugation.
"With fundamental and broad IP protection across our platform, we are well positioned to capitalize on the movement to liquid biopsy, which can save costs for the health care system and most importantly help patients to qualify for treatments that can save or prolong their life," says Kalyan Handique, president and CEO of DeNovo.
